Market Overview

UPDATE: Piper Jaffray Raises PT to $27 on Pacira Pharmaceuticals on Strong Exparel Data Points

Related PCRX
Pacira Pharma Reports Changes to EXPAREL Label, Indication Not Affected
New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events

Piper Jaffray reiterated its Overweight rating on Pacira Pharmaceuticals (NASDAQ: PCRX) and raised the price target from $22.00 to $27.00.

Piper Jaffray noted, “Data points for Pacira's Exparel continue to look favorable, reinforcing our confidence in a strong sales ramp for 2013 and beyond. Institutional sales (wholesale acquisition cost (WAC)-based sales, per Wolters Kluwer (WK), via Bloomberg) for Exparel for December 2012 were around $2.76M, compared to $1.67M in November. Though third party sources generally have done an uneven job of capturing demand, the directional trends dovetail with PCRX's bullish commentary regarding hospital acceptance. We remain confident in our Exparel sales estimates of $70M and $146M in 2013 and 2014, respectively.”

Pacira Pharmaceuticals closed at $19.88 on Friday.

Latest Ratings for PCRX

DateFirmActionFromTo
Oct 2014Bank of AmericaDowngradesBuyNeutral
Aug 2014JefferiesMaintainsBuy
Jul 2014BarclaysMaintainsOverweight

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (PCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional